Synklino logo
VerifiedBiotechnology Research· Founded 2017

Synklino

Synklino is a clinical stage biotechnology company pioneering transformative therapies for solid organ transplantation. Our first-in-class drug candidate, SYN002, is a therapeutic fusion protein designed to eliminate both active and latent CMV infection in donated organs through ex vivo organ perfusion, offering a proactive and life-changing therapy for immunocompromised transplant recipients. With regulatory clearance and funding in place, we are on track to deliver clinical data from kidney transplant recipients through 2026.

7-day free trial · no credit card

HeadquartersCopenhagen Capital Of Denmark, DenmarkEmployees13(1 to 10)Founded year2017Websitesynklino.comLinkedIn profileLinkedIn

Verified contacts

8

available on Kipplo

LinkedIn employees

13

1 to 10 range

Open roles

no listings

Distinct roles

6

indexed titles

Tech stack

0

tools in use

Monthly traffic

organic / mo

Sign up free to see all 8 verified contacts at Synklino

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Decision-makers and verified team members

8 contacts with verified email or phone · masked until revealed.

Sign up free →

Showing 1 of 8 verified contacts

Top roles at Synklino

6 distinct titles indexed · top 6 shown.

  • 1board member
  • 1board observer
  • 1ceo & co-founder
  • 1chief operating officer
  • 1head of discovery
  • 1project director

Sign up to unlock all 8 contacts at Synklino

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Sign up to reveal 8 verified contacts at Synklino

7-day trial · no credit card · cancel anytime · only pay for verified records.

Trusted by sales, marketing, and GTM engineering teams.

Synklino | Kipplo Discover